Children ALL MRD study according to protocol of D. Campana
|
|
- Derick Price
- 6 years ago
- Views:
Transcription
1 Children ALL MRD study according to protocol of D. Campana L.Yu. Grivtsova Laboratory of Haematopoiesis Immunology State N.N.Blokhin Russian Cancer Research Center affiliated to the Russian Academy of Medical Sciences, Russian Federation
2 Risk group stratification Age Leukocyte count Immunophenotype of blasts genetic abberation (BCR/ABL, MLL/AF 4) Therapy induction efficacy (prednisolone response) Leukemic cytoreduction (d 15-th induction chemotherapy)
3 ALL-IC-BFM 2002 (National coordinator from Russia Professor A.V.Popa)
4 Morphological detection of residual disease 7-th & 15-th days therapy of induction Miller et. al Steinherz et al 1996 Sandlund et al 2002
5 Flow cytometry MRD detection Blasts have aberrant immunophenotype G. Janossy et.al. J. of Immunology, 1979, Blood, 1980 M.F. Greaves et. al. Cancer Research, 1981, Blood, 1983
6 BFM-AIEOP Examples of deranged patterns of antigen expression in BCP-ALL with respect to normal differentiation normal frequently involved antigens: CD10, CD11a, CD19, CD20, CD34, CD44, CD45, CD58 M. N. Dworzak et. al CCRI St. Anna Kinderspital, Vienna, Austria
7 A leukemic preb- C-ALL physiologic 34 + BCP 34 - BCP global B leukemic preb- C-ALL physiologic BCP1 BCP2 BCP3 BFM-AIEOP % overexpression MFI MFI 100 Deranged patterns of antigen expression in BCP-ALL CD % underexpression CD45 RA with respect to normal differentiation C 1000 leukemic preb- C-ALL physiologic BCP1 BCP2 BCP3 D leukemic preb- C-ALL physiologic BCP1 BCP2 BCP3 M. N. Dworzak et. al CCRI St. Anna Kinderspital, Vienna, Austria 100 MFI % underexpression CD11a 1000 MFI % underexpression CD 44
8 BFM-AIEOP normal Examples of deranged patterns of antigen expression in BCP-ALL with respect to normal differentiation frequently involved antigens: CD10, CD11a, CD19, CD20, CD34, CD38, CD44, CD45, CD58 M. N. Dworzak et. al CCRI St. Anna Kinderspital, Vienna, Austria
9 Comparison of established MRD-MoAb panels St. Jude CRH AIEOP-BFM Biomed MyM cym c TdT Cµ WT a ( ) limited panel!! triple-backbone! TdT (19) CD diversity: n= 17 n= 10 n= 12
10 Mini Mini study results (Prague -2007) BFM-AIEOP Patients: Czechia, Croatia, Hong Kong, Hungary, Israel Syto16/CD19/CD45 CD20/CD10/CD19/CD34 CD58/CD10/CD19/CD34 CD10/CD66c/CD19/CD45 standard subpopulations evaluated regardless initial immunophenotype normal immature cells with the same immunophenotype typical rebound regeneration after chemotherapy
11 Mini Mini study results (Prague -2007) BFM-AIEOP Live gate strategy (syto 16 all nucleated cells)
12 Mini Mini study results (Prague -2007) BFM-AIEOP cells expressing aberrant molecules CD20/CD10/CD19/CD34 CD58/CD10/CD19/CD34 CD10/CD66c/CD19/CD45
13 Mini Mini study results (Prague -2007) BFM-AIEOP BCP ALL: CD
14 Mini Mini study results (Prague -2007) BFM-AIEOP BCP ALL CD10-66c-19-45
15 Mini Mini study results (Prague -2007) BFM-AIEOP
16 Mini Mini study results (Prague -2007) BFM-AIEOP Waiting for the antibodies PC5 DAKO PE BD
17 Mini Mini study results (Prague -2007) BFM-AIEOP 4-color FC - four to one tube CD19 PC5 to PC7 planned change as PC7 became available other changes (Coulter based system) CD66c conjugated with FITC changes in SYTO16 combinations (SYTO16-CD10-CD19-CD45) SYTO16 combination not measured extra templates needed SR: FCM-MRD d15 < 0.1% NC MR: FCM-MRD d15 >=0.1% NC, HR: FCM-MRD d15 > 10% NC.
18 Coustan-Smith E. et al. Blood, 2006 BM normal lymphoid progenitors CD10+CD19+CD34+ are exquisitely sensitive to corticosteroids and other antileukemic drugs In patients with B-lineage ALL cells with this phenotype detected early in treatment shoud be leukemic rather than normal
19 Coustan-Smith E. et al. Blood, 2006 Three-color FC (BCP ALL) T-Lineage ALL after 2 weeks of remission induction therapy (day +19) CD19+CD34+ and/or CD19+CD10+ undetecteble or represented less than 0,01% of BM MNC
20 Coustan-Smith E. et al. Blood, 2006 Three-color FC (BCP ALL 380 pts) FSC vs SSC events (cells) CD19 gating CD10 CD34 PerCP- PE - FITC SR IR HR 0,01- <0,1%% 0,1 - < 1,0%% 1,0% and more MNC MNC MNC
21 Coustan-Smith E. et al. Blood, 2006 Three-color FC (BCP ALL)
22 Coustan-Smith E. et al. Blood, 2006 Three-color FC (BCP ALL)
23 Coustan-Smith E. et al. Blood, 2006 Three-color FC (BCP ALL)
24 Study design Started - Spring 2007 National coordinator from Russia Professor A.V.Popa 1. Flow cytometric assay according to Coustan-Smith E. et al. Blood, Measurement of blast percent (morphology) and CD10+CD19+ as well as CD34+CD19+ MNC (MNC were identified according to FSC/SSC) Day 15 of induction therapy Day 33 of induction therapy
25 Study design 21 pts Pre-pre-B ALL day pts day pts Morphology FC IgG1 PE IgG1FITC- CD19PE-cy5 Typical morphology of lymphoblast L1-L2 CD10PE- CD34 FITC CD19PE-cy5 or CD34PE- CD10 FITC CD19PE-cy5
26 Day +15 group I (morphology CR, blasts 0,0-1,0) n pts % blasts of morfology %CD19+CD10+ of MNC %CD19+CD34+ of MNC 1 Kalant. 0,6 0,39 0,33 2 Lob. 1,0 1,49 1,0 3 Min. 0,5 0,04 0,0 4 Lin. 0,0 0,01 0,57 5 Redzh. 0,0 0,54 <0,01 6 Les. 0,7 0, Grig. 0,0 0,0 0,0 8 Karp. 0,0 0,04 0,14 9 Gadz 0,2 0,01 1,7 10 Shaik. 0,2 0,0 0,0 Only 2 cases of complete morphological and FC remission (<0,01% MNC CD19+CD10+CD34+)
27 EXAMPLE MRD in BCP ALL Complete morphological (0% blasts) and FC remission (<0,01% MNC CD19+CD10+CD34+) A C D CD10 PE CD34 FITC B Patient G Day 15 Morphology 0,0% blasts FC 0,0% MNC (CD19+CD10+& CD19+CD34+)
28 EXAMPLE, MRD in BCP ALL Patient R, day 15 Morphologically 0% blasts Flow MRD <1,0% CD10+CD19+ & CD34+CD19+ MNC A B C D CD19+CD10+ 0,74% of MNC CD19+CD34+ 0,04% of MNC
29 Day +15 group II (morphologically blasts 1,1-5,0) n pts % blasts of morfology %CD19+CD10+ of MNC %CD19+CD34+ of MNC 1 Zhul. 3,4 3,3 1,1 2 Ilnits. 3,2 0,12 0,05 3 Vor. 2,0 0,08 0,06 4 Tash. 1,5 1,46 0,16 5 Saf. 2,4 0, Zhuik. 1, Siv 4,5 0,43 0,05 In 1 case (blasts 1%) FC not detected of MRD(0% MNC CD19+CD34+CD10+) In 6 cases flow cytometrically MRD (0,06 3,3%) MNC
30 EXAMPLE MRD in BCP ALL (intermediate group) Patient Zuik., day 15 Morphologically 1,5% blasts A B CD19+CD10+ CD19+CD34+ FC MRD 0,0% CD10+CD19+ & CD34+CD19+ MNC
31 EXAMPLE MRD in B-lineage ALL (intermediate group) Patient T., BCP All Day 15 Morphology - Blasts 1,5% FC MRD CD19+CD10+ CD19+CD34+ 1,46% MNC 0,16% MNC A B CD19+CD10+ CD19+CD34+
32 Day +15 group III (morphological blasts >5,0%) n pts % blasts of morphology %CD19+CD10+ of MNC %CD19+CD34+ of MNC 1 Bulig. 60,8 58,9 52,2 2 Mustaf. 8,2 2,85 1,15 3 Khleb. 17,5 28,7 20,4 4 Kisel. 16,0 20,8 0,01 In all these cases it was a prominent percent of CD10+CD19+ & CD34+CD19+ MNC CD19+CD10+ 28,7% of MNC CD19+CD34+ 14,17% of MNC Morphologycally 17,5% blasts
33 FC MRD Day pts Mean Median variabl n Morphology blasts CD19+CD10+ MNC CD19+CD10+ MNC 1,2+/-0,35 0,8 0,0-5,8 18 2,06+/-2,01 0,02 0,0-36,4 18 0,87+/-0,84 0,015 0,0-15,3 18
34 FC MRD Day pts Pts Blasts morfjlogycally (%%) CD19+CD10+ (%% MNC) CD19+CD34+ (%% MNC) Zhul. 3,6 0,04 0,0 Il. 1,4 0,09 0,03 Bu. 5,8 36,4 15,3 Kal. 0 0,07 0,0 Lo. 0,9 0,36 0,22 V. 0,0 0,01 0,0 Mu. 1,5 0,04 0,0 Khl. 2,2 0,09 0,12 Mi. 0 0,02 0,02 T. 1,2 0,01 0,02 G. 0,8 0,06 0 Kar. 2,6 0,02 0,05 Sha. 0,2 0,0 0,01 S. 0 0,0 0,0 R. 0,4 0,01 0,0 Le. 2,6 0,01 0 Zhui Ga 0,4 0 0
35 Summary, conclusions Day 15 Morphologically remission was noted in 17 of 21 pts (blasts not more than 5%) In group (10pts) where morphologycally blasts not more than 1,0%, flow cytometrically MRD was not noted in 2 cases. In cases (11 pts), where morphologically there were more than 1% of blasts in BM, flow cytometry confirmed MRD in 10 cases. Only in 1 pt with 1,5% blasts morphologically, FC not detect MRD (CD19+CD34+CD10+ MNC). So, in 3 from 17 cases with morphological remission (blasts less then 5%) immunologically MRD was not identified. These pts are possible candidates for reduction of intensity of induction therapy. Day 33 Morphologically less then 1% blasts were identified in 10 of 18 pts. In these cases flow cytometrically MRD was not noted in 6 cases (0,01 and less CD19+CD10+&CD19+CD34+ MNC cells. In 7 of 8 cases, where morphologically there were more than 1% of blasts in BM, flow cytometry confirmed MRD. Only in 1 pts (2,6% blasts morphologically) FC did not detect CD19+CD34+CD10+ MNC.
36 Children ALL MRD study State N.N..Blokhin Russian Cancer Research Center affiliated to the Russian Academy of Medical Sciences, Russian Federation Отделение химиотерапии гемобластозов НИИ ДО и Г ГУ РОНЦ им. Н.Н. Блохина РАМН Рук. Профессор А.В. Попа Лаборатория иммунологии гемопоэза Централизованный клиниколабораторный отдел НИИ КО ГУ РОНЦ им. Н.Н. Блохина РАМН Рук. Профессор Н.Н. Тупицын Лаборатория гемоцитологии НИИ ДО и Г ГУ РОНЦ им. Н.Н. Блохина РАМН Рук. Профессор И.И. Матвеева M. Г. Божьева Л.Ю. Гривцова И.Н. Серебрякова Н.А. Купрышина
37 Thanks a lot of attention!!!
The spectrum of flow cytometry of the bone marrow
The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests
More informationVUmc Basispresentatie
Clinical diagnostic cytometry Gerrit J Schuurhuis Dept of Hematology VU University Medical Center Amsterdam, Netherlands Use of immunophenotyping at diagnosis to trace residual disease after therapy 1.
More informationFlow cytometry leukocyte differential : a critical appraisal
Flow cytometry leukocyte differential : a critical appraisal Francis Lacombe Flow cytometry department University Hospital of Bordeaux, Pessac, France francis.lacombe@chu-bordeaux.fr 2008 HORIBA ABX, All
More informationAIEOP-BFM consensus guidelines 2016 flow cytometric immunophenotyping in pediatric acute leukemias
AIEOP-BFM consensus guidelines 2016 flow cytometric immunophenotyping in pediatric acute leukemias Michael N. Dworzak St. Anna Children s Cancer Research Institute Vienna, Austria, EU ibfm FLOW network
More informationDr Prashant Tembhare
Dr Prashant Tembhare docprt@gmail.com FCM very powerful technology in Identification and characterization of neoplastic plasma cells as it allows - simultaneous assessment of multiple antigens large numbers
More informationKerrie Clerici, Michael Swain, Dominic Fernandez, Julia Schulz, Matthew Archer, Janine Campbell
Minimal Residual Disease (MRD) Testing by Flow Cytometry for childhood Precursor B Cell Acute Lymphoblastic Leukaemia Royal Children s Hospital experience. Kerrie Clerici, Michael Swain, Dominic Fernandez,
More informationSUPPLEMENTARY FIG. S3. Kaplan Meier survival analysis followed with log-rank test of de novo acute myeloid leukemia patients selected by age <60, IA
Supplementary Data Supplementary Appendix A: Treatment Protocols Treatment protocols of 123 cases patients were treated with the protocols as follows: 110 patients received standard DA (daunorubicin 45
More informationTools for MRD in AML: flow cytometry
ACUTE MYELOID LEUKEMIA MEETING Ravenna - October 27, 2017 Tools for MRD in AML: flow cytometry Francesco Buccisano Can MRD improve outcome determina3on? No. of leukemic cells 10 12 10 10 10 8 10 6 10 4
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationFLOW CYTOMETRIC ANALYSIS OF NORMAL BONE MARROW
XI International Conference Hematopoiesis Immunology Budapest, June 6-7, 2014 FLO CYTOMETRIC ANALYSIS OF NORMAL BONE MARRO Bruno Brando and Arianna Gatti Hematology Laboratory and Transfusion Center Legnano
More informationAn adequate diagnosis is the first goal towards
Acute Leukemias New methodologic approaches for immunophenotyping acute leukemias trends in hematology haematologica 2001; 86:675-692 http://www.haematologica.it/2001_07/0675.htm GIUSEPPE BASSO, BARBARA
More informationStandard immunophenotyping of leukemia cells in acute myeloid leukemia (AML)
Clinical immunology Standard immunophenotyping of leukemia cells in acute myeloid leukemia (AML) ` JOLANTA WOZNIAK, JOANNA KOPEÆ-SZLÊZAK Department of Haematological Cytobiology, Institut of Haematology
More informationCME. The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia
Hematopathology / Minimal Residual Disease in AML The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia Adhra Al-Mawali, PhD, 1-3 David Gillis, MBBS,
More informationTowards the study of bone marrow DTC in breast and ovarian cancer
Towards the study of bone marrow DTC in breast and ovarian cancer Nikolay Tupitsyn FSBI N.N.Blokhin Russian Cancer Research Center, the Russian Academy of Medical Sciences MOSCOW, RUSSIA HAEMATOPOIESIS
More informationOriginal article. Key words: Lymphoblastic leukemia, Acute, Childhood, Minimal residual disease, Flow cytometry
Original article DOI: 10.5/kjp.2010.5.11.957 Korean J Pediatr 2010;5(11):957-96 Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction
More informationMultiparameter flow cytometry can be used to
Minimal residual disease testing in Acute Leukemia Anjum Hassan MD Assistant Professor of Pathology and Immunology, Director FISH laboratory in Anatomic Pathology, Washington University in St Louis, School
More informationCLINICAL USE OF CELLULAR SUBPOPULATION ANALYSIS IN BM
CLINICAL USE OF CELLULAR SUBPOPULATION ANALYSIS IN BM CANCER RESEARCH CENTRE, UNIVERSITY AND UNIVERSITY HOSPITAL OF SALAMANCA (SPAIN)( Sao Paulo, 18th of April, 2009 IDENTIFICATION OF HPC (I) 1.- In vivo
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationSummary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5):
Rep Pract Oncol Radiother, 2007; 12(5): 283-288 Preliminary Communication Received: 2007.03.27 Accepted: 2007.07.24 Published: 2007.10.18 Authors Contribution: A Study Design B Data Collection C Statistical
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationMRD in ALL: Correct interpretation in clinical practice. Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh
MRD in ALL: Correct interpretation in clinical practice Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh Minimal residual disease Subclinical level of residual leukemia Below
More informationClinical question. Screening tube. Diagnostic panel MRD. Clinical question
OW CYTOMETRY UPDATES IN LYMPHOPROLIFERATIVE DISORDERS CANCER RESEARCH CENTER IBSAL UNIVERSITY & UNIVERSITY HOSPITAL, SALAMANCA (SPAIN) DISCLOSURES The EuroFlow Scientific Consortium Iamco-chairof receives
More informationHematology MUHAMMAD M. KHURRAM* SAGHIR A. JAFRI* ABDUL MANNAN** AFTAB NADEEM*** ASIF JAMAL*
Hematology FREQUENCY OF ABERRANT EXPRESSION OF CD MARKERS IN CASES OF ACUTE LEUKEMIA MUHAMMAD M. KHURRAM* SAGHIR A. JAFRI* ABDUL MANNAN** AFTAB NADEEM*** ASIF JAMAL* SUMMARY: In the present study 100 patients
More informationMeeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD
Meeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD What is it? clonal expansion of myeloid precursor cells with reduced capacity to differentiate as opposed to ALL/CLL, it is limited to the myeloid cell
More informationNormal & Leukaemic haematopoiesis. Dr. Liu Te Chih Dept of Haematology / Oncology National University Health Services Singapore
Normal & Leukaemic haematopoiesis 2010 Dr. Liu Te Chih Dept of Haematology / Oncology National University Health Services Singapore Use of Immunophenotyping today Lineage assignment Differentiation of
More informationG-CSF-primed autologous and allogeneic bone marrow for transplantation in clinical oncology. Cell content and immunological characteristics
Journal of Physics: Conference Series PAPER OPEN ACCESS G-CSF-primed autologous and allogeneic bone marrow for transplantation in clinical oncology. Cell content and immunological characteristics To cite
More informationDo Your Flow Cytometric LDTs. Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine
Do Your Flow Cytometric LDTs Conform to the ICSH ICCS Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine How should LDTs be validated? Accuracy Specificity Sensitivity
More informationSignificant CD5 Expression on Normal Stage 3 Hematogones and Mature B Lymphocytes in Bone Marrow
Hematopathology / CD5 Expression on Normal B Cells Significant CD5 Expression on Normal Stage 3 Hematogones and Mature B Lymphocytes in Bone Marrow Franklin S. Fuda, DO, Nitin J. Karandikar, MD, PhD, and
More informationMultidimensional Flow Cytometry for Detection of Rare Populations in Hematological Malignancies
TZU CHI MED J March 2009 Vol 21 No 1 available at http://ajws.elsevier.com/tcmj Tzu Chi Medical Journal Original Article Multidimensional Flow Cytometry for Detection of Rare Populations in Hematological
More informationMonitoring of T-cell Acute Lymphoblastic Leukemia by Flow Cytometry
Cent. Eur. J. Med. 5(6) 2010 651-658 DOI: 10.2478/s11536-010-0044-3 Central European Journal of Medicine Monitoring of T-cell Acute Lymphoblastic Research Article Miglė Janeliūnienė 1,2*, Rėda Matuzevičienė
More informationImmunophenotypic study of acute leukemia by flow cytometry at BPKMCH.
Nepal Medical Association Building Exhibition Road, Kathmandu Journal of Pathology of Nepal (2013) Vol. 3, 345-350 Association of Clinical Pathologist of Nepal-2010 Journal of PATHOLOGY of Nepal www.acpnepal.com
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationMRD detection in AML. Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome
MRD detection in AML Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome Determinants of Treatment Response Leukemia Tumor burden Growth potential Drug resistance Karyotype Genetics Host
More informationBD Flow Cytometry Reagents Multicolor Panels Designed for Optimal Resolution with the BD LSRFortessa X-20 Cell Analyzer
Multicolor Panels Designed for Optimal Resolution with the BD LSRFortessa X-2 Cell Analyzer Proper multicolor panel design takes into account fluorochrome brightness, antigen density, co-expression, and
More informationCME/SAM. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens
Hematopathology / Flow Cytometric Immunophenotyping of CSF Specimens Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens Fiona E. Craig, MD, 1 N. Paul Ohori, MD, 2 Timothy S. Gorrill, MD,
More informationApplication Information Bulletin: Human NK Cells Phenotypic characterizing of human Natural Killer (NK) cell populations in peripheral blood
Application Information Bulletin: Human NK Cells Phenotypic characterizing of human Natural Killer (NK) cell populations in peripheral blood Christopher A Fraker, Ph.D., University of Miami - Miami, Florida
More informationAdult ALL: NILG experience
Adult ALL: NILG experience R Bassan USC Ematologia, Ospedali Riuniti, Bergamo SIE Interregionale, Padova 12 5 2011 Now and then Northern Italy Leukemia Group 2000-10 Prospective clinical trials 09/00 10/07
More informationNormal Blood and Bone Marrow Populations
4 CHAPTER 4 Normal Blood and Bone Marrow Populations It is essential to have a sound understanding of the nature and immunophenotypic characteristics of the normal cell populations encountered in bone
More informationWelcome. Welcome. Emerging Technologies in Flow Cytometry
Emerging Technologies in Flow Cytometry Dr. William Dittman December 11, 2012 You may download a copy of the handout by clicking on the handout icon, located in the upper right hand corner of your screen
More informationTest Utilization: Chronic Lymphocytic Leukemia
Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.
More informationSupplementary Materials
Supplementary Materials 43 Figure S1. CD123 in acute lymphoblastic leukemia and leukemia-initiating cells. A. CD123 (histograms) is highly and homogenously expressed in B-ALL blasts (as defined by live,
More informationx Lymphocyte count /µl CD8+ count/µl 800 Calculated
% Lymphocyte in CBC A. 50 40 30 20 10 Lymphocyte count /µl B. x10 3 2.5 1.5 C. 50 D. 1000 % CD3+CD8+ Cells 40 30 20 Calculated CD8+ count/µl 800 600 400 200 10 0 #61 #63 #64 #65 #68 #71 #72 #75 Figure
More informationOriginal Article Acute Leukemias And Aberrant Markers Expression Pak Armed Forces Med J 2018; 68 (3):
Open Access Original Article Acute Leukemias And Aberrant Markers Expression Pak Armed Forces Med J 2018; 68 (3): 450-54 SPECTRUM OF ACUTE LEUKEMIAS AND ABERRANT MARKERS EXPRESSION BASED ON FLOWCYTOMETRY
More informationMRD Evaluation The Austrian experience
MRD Evaluation The Austrian experience Gabriele Brachtl Molekularzytologisches Labor III. Medical Department of Hematology, Oncology, Hemostaseology, Rheumatology and Infectiology Head: Univ. Prof. Dr.
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationMeasuring Dendritic Cells
Measuring Dendritic Cells A.D. Donnenberg, V.S. Donnenberg UNIVERSITY of PITTSBURGH CANCER INSTITUTE CCS Longbeach 10_04 Measuring DC Rare event detection The basics of DC measurement Applications Cancer
More informationTCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations.
Supplementary Figure 1 TCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations. The CpG motifs closest to the breakpoints are highlighted in red boxes and the
More informationJournal of the Egyptian Nat. Cancer Inst., Vol. 13, No. 3, September: , 2001
Journal of the Egyptian Nat. Cancer Inst., Vol. 13, No. 3, September: 191-201, 2001 Expression of the C-KIT Molecule in Acute Myeloid Leukemias: Implications of the Immunophenotypes CD117 and CD15 in the
More informationBumps on the Neck and Groin of a 2-Year-Old Male. Laboratory Findings: Table 1, Table 2; Figure 1; Image 1, Image 2, Image 3
Bumps on the Neck and Groin of a 2-Year-Old Male 1 Erikakelly Strand, BS* Clinical History Patient: 2-year-old white male. Chief Complaint: Bumps on neck and groin. History of Present Illness: A 2-year-old
More informationSupplementary Table; Supplementary Figures and legends S1-S21; Supplementary Materials and Methods
Silva et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability Supplementary Table; Supplementary Figures and legends S1-S21; Supplementary
More informationFlow Cytometric Analysis of Cerebral Spinal Fluid Involvement by Leukemia or Lymphoma
Flow Cytometric Analysis of Cerebral Spinal Fluid Involvement by Leukemia or Lymphoma Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, DCS, NCI, NIH DEPARTMENT OF
More informationTargeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD
Targeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD Harvard/Dana-Farber Cancer Institute Boston, MA Disclosures for Daniel J. DeAngelo, MD, PhD Royalty Receipt of intellectual property/ Patent
More informationFlow cytometry for MRD detec1on: Focus on AML. Sindhu Cherian University of Washington, Sea6le, WA, USA
Flow cytometry for MRD detec1on: Focus on AML Sindhu Cherian University of Washington, Sea6le, WA, USA Residual disease in hematopoie1c malignancy Residual disease has tradi:onal been defined by morphology
More informationSupplementary Figure 1. BMS enhances human T cell activation in vitro in a
Supplementary Figure 1. BMS98662 enhances human T cell activation in vitro in a concentration-dependent manner. Jurkat T cells were activated with anti-cd3 and anti-cd28 antibody in the presence of titrated
More informationA step-by-step approach to build and analyze a multicolor panel
Analyze A step-by-step approach to build and analyze a multicolor panel For Research Use Only. Not for use in diagnostic or therapeutic procedures. Alexa Fluor is a registered trademark of Life Technologies
More informationPersistent lymphocytosis. Persistent lymphocytosis: are there prognostic indicators? Problem. Questions. Basic markers used to identify lymphocytes
Persistent lymphocytosis Persistent lymphocytosis: are there prognostic indicators? Paul R. Avery VMD, PhD, DACVP Marjorie Williams, DVM Anne C. Avery VMD, PhD Clinical Immunology Laboratory Colorado State
More informationTHE USE OF WT1-QPCR TO MEASURE AND DETECT MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA. Ava Greco
THE USE OF WT1-QPCR TO MEASURE AND DETECT MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA Ava Greco REVIEW OF LITERATURE What is Leukemia? Abnormal growth of cells in the blood stream Progresses rapidly
More informationPearson r = P (one-tailed) = n = 9
8F4-Specific Lysis, % 1 UPN1 UPN3 8 UPN7 6 Pearson r =.69 UPN2 UPN5 P (one-tailed) =.192 4 UPN8 n = 9 2 UPN9 UPN4 UPN6 5 1 15 2 25 8 8F4, % Max MFI Supplementary Figure S1. AML samples UPN1-UPN9 show variable
More informationsequences of a styx mutant reveals a T to A transversion in the donor splice site of intron 5
sfigure 1 Styx mutant mice recapitulate the phenotype of SHIP -/- mice. (A) Analysis of the genomic sequences of a styx mutant reveals a T to A transversion in the donor splice site of intron 5 (GTAAC
More informationMyelodysplastic scoring system with flow cytometry. G Detry B Husson
Myelodysplastic scoring system with flow cytometry G Detry B Husson Myelodysplastic syndroms Clonal haematopoietic stem cell disease characterized by dysplasia in one or more of the myeloid cell lines
More informationORIGINAL ARTICLE. A van Rhenen 1, B Moshaver 1, A Kelder 1, N Feller 1, AWM Nieuwint 2, S Zweegman 1, GJ Ossenkoppele 1 and GJ Schuurhuis 1
(2007) 21, 1700 1707 & 2007 Nature Publishing Group All rights reserved 0887-6924/07 $30.00 www.nature.com/leu ORIGINAL ARTICLE Aberrant marker expression patterns on the CD34 þ CD38 stem cell compartment
More informationSupplementary Figure S1. Flow cytometric analysis of the expression of Thy1 in NH cells. Flow cytometric analysis of the expression of T1/ST2 and
Supplementary Figure S1. Flow cytometric analysis of the expression of Thy1 in NH cells. Flow cytometric analysis of the expression of T1/ST2 and Thy1 in NH cells derived from the lungs of naïve mice.
More information23/10/2017. Analysis of bone marrow for MDSrelated. Approach used at Hematopathology, Lund
Approach used at Hematopathology, Lund Analysis of bone marrow for MDSrelated aberrancies According to International/ELN Flow Cytometry Working Group (IMDSFlow) Anna Porwit Lund, Sweden 1. new patients
More informationUse of Flow Cytometry Immunophenotyping for Diagnosis of Acute Leukemia at Moi Teaching and Referral Hospital, Eldoret, Kenya
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) ISSN (Print) 2313-4410, ISSN (Online) 2313-4402 Global Society of Scientific Research and Researchers http://asrjetsjournal.org/
More informationFLOW CYTOMETRY PRINCIPLES AND PRACTICE. Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018
FLOW CYTOMETRY PRINCIPLES AND PRACTICE Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018 Aims and Objectives Principles of flow cytometry Preparation Steps involved
More informationCD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow
White Paper September 2016 CD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow Lily C. Trajman, PhD Introduction: Hematopoietic Stem Cells (HSCs)
More informationACUTE LYMPHOBLASTIC LEUKEMIA
ACUTE LYMPHOBLASTIC LEUKEMIA YOUNG ADULT PATIENT Highlights clonoseq Tracking (MRD) Testing in the peripheral blood revealed early signs of relapse post-transplant Patient achieved remission after CAR-T
More informationIntroduction LYMPHOID NEOPLASIA
LYMPHOID NEOPLASIA Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies Nicola Gökbuget,
More informationAbstract. Hematopathology / HEMATOGONE POPULATIONS
Hematopathology / HEMATOGONE POPULATIONS Benign Hematogone-Rich Lymphoid Proliferations Can Be Distinguished From B-Lineage Acute Lymphoblastic Leukemia by Integration of Morphology, Immunophenotype, Adhesion
More informationIdentification of residual leukemic cells by flow cytometry in childhood
Brief Report Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic
More informationHandout for lecture on lymphoblastic neoplasms presented by Rob McKenna
Handout for lecture on lymphoblastic neoplasms presented by Rob McKenna The following slides represent a near final version of the presentation that will be given in Maui, January 23,2018. Minor changes
More informationSignificance of myeloid antigen expression in precursor T lymphoblastic lymphoma
窑 Clinical Research 窑 Chinese Journal of Cancer Significance of myeloid antigen expression in precursor T lymphoblastic lymphoma Yue Cai 1,2, Xiao Fei Sun 1,2, Su Li Yan 1,3, Zi Jun Zhen 1,2, Yi Xia 1,2,
More informationDetailed step-by-step operating procedures for NK cell and CTL degranulation assays
Supplemental methods Detailed step-by-step operating procedures for NK cell and CTL degranulation assays Materials PBMC isolated from patients, relatives and healthy donors as control K562 cells (ATCC,
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
V O L U M E 2 6 N U M B E R 1 8 J U N E 2 0 2 0 0 8 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With
More informationTube 1 : FLAER/CD24/CD16/CD15/CD45
Gating procedure for white blood cells (WBC) on FC500 The French PNH diagnosis working group has developed an optimized gating strategy adapted to a two-tubes diagnostic test (PMN, MO), evaluated in a
More informationDiagnóstico y clasificación de los sindromes linfoproliferativos crónicos B
Diagnóstico y clasificación de los sindromes linfoproliferativos crónicos B CENTRO DE INVESTIGACIÓN DEL CANCER & SERVICIO DE CITOMETRIA UNIVERSIDAD DE SALAMANCA Buenos Aires; Argentina. 30-31 mayo 1 junio
More informationMS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD
MS.4/ 27.02.2019 Acute Leukemia: AML Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising
More informationMinimal residual disease: optimal methods, timing, and clinical relevance for an individual patient
DYNAMIC DISCOVERIES AND DIRECTIONS IN PEDIATRIC LEUKEMIAS Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient Martin Schrappe 1 1 Department of Pediatrics
More informationBLOOD RESEARCH ORIGINAL ARTICLE INTRODUCTION. Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
BLOOD RESEARCH VOLUME 49 ㆍ NUMBER 4 December 2014 ORIGINAL ARTICLE Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic
More informationSuccessful flow cytometric immunophenotyping of body fluid specimens
Successful flow cytometric immunophenotyping of body fluid specimens Fiona E. Craig, MD Division of Hematopathology Mayo Clinic Arizona 2017 MFMER slide-1 Financial disclosure No conflicts 2017 MFMER slide-2
More informationMonocyte subsets in health and disease. Marion Frankenberger
Monocyte subsets in health and disease Marion Frankenberger main cellular components: Leukocytes Erythrocytes Composition of whole blood Monocytes belong to the cellular components of peripheral blood
More informationFlow Cytometric Analysis of CD5+ B Cells A Frame of Reference for Minimal Residual Disease Analysis in Chronic Lymphocytic Leukemia
Hematopathology / CD5+ -CELL NLYSIS Y FLOW CYTOMETRY Flow Cytometric nalysis of CD5+ Cells Frame of Reference for Minimal Residual Disease nalysis in Chronic Lymphocytic Leukemia Ritu Gupta, MD, 1 Paresh
More informationMBL in Blood Donors: An Extended Immunophenotypic Analysis of CLL-like, CD5+ MBL.
1 th Canadian CLL Meeting Winnipeg, Manitoba Inn at the Forks September 18-19, 214 MBL in Blood Donors: An Extended Immunophenotypic Analysis of CLL-like, CD5+ MBL. Fatima Abbasi 1, Justin Meskas 2, Ryan
More informationCHAPTER 3 LABORATORY PROCEDURES
CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified
More informationa Beckman Coulter Life Sciences: White Paper
a Beckman Coulter Life Sciences: White Paper An 8-color DuraClone IM panel for detection of Human blood dendritic cells by flow cytometry Nathalie Dupas 1, Snehita Sattiraju 2, Neha Girish 2, Murthy Pendyala
More informationOnline supplement. Phenotypic, functional and plasticity features of classical and alternatively activated
Online supplement Phenotypic, functional and plasticity features of classical and alternatively activated human macrophages Abdullah Al Tarique*, Jayden Logan *, Emma Thomas *, Patrick G Holt *, Peter
More informationCirculating Endothelial Cells and Their Clinical Significance Jaco Kraan
Circulating Endothelial Cells and Their Clinical Significance Jaco Kraan Department of Medical Oncology Erasmus MC Cancer Institute Rotterdam, The Netherlands ISLH 2016 - Milano, Italy Financial disclosure
More informationSupplementary Figure 1. Successful excision of genes from WBM lysates and
Supplementary Information: Supplementary Figure 1. Successful excision of genes from WBM lysates and survival of mice with different genotypes. (a) The proper excision of Pten, p110α, p110α and p110δ was
More informationNature Immunology: doi: /ni Supplementary Figure 1. Examples of staining for each antibody used for the mass cytometry analysis.
Supplementary Figure 1 Examples of staining for each antibody used for the mass cytometry analysis. To illustrate the functionality of each antibody probe, representative plots illustrating the expected
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationChronic lymphocytic leukemia is eradication feasible and worthwhile?
Chronic lymphocytic leukemia is eradication feasible and worthwhile? Gianluca Gaidano, MD, PhD Division of Hematology Department of Clinical and Experimental Medicine Amedeo Avogardo University of Eastern
More informationwell for 2 h at rt. Each dot represents an individual mouse and bar is the mean ±
Supplementary data: Control DC Blimp-1 ko DC 8 6 4 2-2 IL-1β p=.5 medium 8 6 4 2 IL-2 Medium p=.16 8 6 4 2 IL-6 medium p=.3 5 4 3 2 1-1 medium IL-1 n.s. 25 2 15 1 5 IL-12(p7) p=.15 5 IFNγ p=.65 4 3 2 1
More informationFluorochrome Panel 1 Panel 2 Panel 3 Panel 4 Panel 5 CTLA-4 CTLA-4 CD15 CD3 FITC. Bio) PD-1 (MIH4, BD) ICOS (C398.4A, Biolegend) PD-L1 (MIH1, BD)
Additional file : Table S. Antibodies used for panel stain to identify peripheral immune cell subsets. Panel : PD- signaling; Panel : CD + T cells, CD + T cells, B cells; Panel : Tregs; Panel :, -T, cdc,
More informationBD Multitest IMK Kit
BD Multitest IMK Kit 50 Tests Catalog No. 340503 50 Tests with BD Trucount Tubes Catalog No. 340504 IVD 2016 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company.
More informationCorrespondence should be addressed to Eric X. Wei;
Hindawi Case Reports in Hematology Volume 217, Article ID 587315, 7 pages https://doi.org/1.1155/217/587315 Case Report γδ T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Discussion of Two Pediatric Cases
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationMinimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital
Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical
More informationMinimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials
Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials Fda.gov Adriano Venditti Hematology, University Tor Vergata, Rome, Italy Minimal Residual Disease 10 12 Relapse
More informationPAX5-JAK2 fusion in acute lymphoblastic leukaemia. Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne
PAX5-JAK2 fusion in acute lymphoblastic leukaemia Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne Case 12-year-old girl Diagnosed with BCP ALL in November 2015 Presenting WCC 35x10
More informationFlow Cytometry Applications in Hematological Diseases. Case Study. Sa A. Wang, MD Dept. of Hematopathology UT MD Anderson Cancer Center
Flow Cytometry Applications in Hematological Diseases Case Study Sa A. Wang, MD Dept. of Hematopathology UT MD Anderson Cancer Center ASCP 2011, Las Vegas Objectives Using case presentation format to illustrate
More information